| 0.5302 -0.42 (-44.2%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.98 |
1-year : | 1.22 |
| Resists | First : | 0.84 |
Second : | 1.04 |
| Pivot price | 0.83 |
|||
| Supports | First : | 0.5 |
Second : | 0.42 |
| MAs | MA(5) : | 0.87 |
MA(20) : | 0.83 |
| MA(100) : | 0.82 |
MA(250) : | 2.26 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 45.1 |
D(3) : | 60.3 |
| RSI | RSI(14): 31.9 |
|||
| 52-week | High : | 7.28 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ATYR ] has closed below the lower bollinger band by 18.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ATYR ] is to continue within current trading range. It is unclear right now based on current values. 130.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.8 - 0.81 | 0.81 - 0.81 |
| Low: | 0.5 - 0.51 | 0.51 - 0.51 |
| Close: | 0.52 - 0.53 | 0.53 - 0.54 |
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Tue, 12 May 2026
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Tue, 12 May 2026
aTyr Pharma stock tumbles on new Phase 3 trial plans - Investing.com
Mon, 11 May 2026
aTyr Pharma (ATYR) Advances Development of Efzofitimod in Pulmon - GuruFocus
Mon, 11 May 2026
aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial - Yahoo Finance
Mon, 11 May 2026
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com
Mon, 11 May 2026
FDA feedback guides aTyr Pharma (NASDAQ: ATYR) toward new Phase 3 sarcoidosis trial - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 9.561e+007 (%) |
| Held by Institutions | 2.4 (%) |
| Shares Short | 18,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.696e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -40 % |
| Return on Assets (ttm) | 856.3 % |
| Return on Equity (ttm) | -51.2 % |
| Qtrly Rev. Growth | 190000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -166.33 |
| EBITDA (p.s.) | -9.23538e+007 |
| Qtrly Earnings Growth | -0.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.49 |
| Dividend | 0 |
| Forward Dividend | 1.988e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|